New prostate cancer drug shows promising results in a clinical trial led by Yale University

A first-of-its-kind drug showed promising results in a clinical trial led by a Yale University team, reducing tumor activity and pain in patients with metastatic prostate cancer. Researcher Daniel Petrylak described it as a first-in-class drug for this disease.

AI-written summary of 2 sources; every verified point is backed by a verbatim quote. How Iyan works

• The study was led by a Yale University team and published in the Journal of Clinical Oncology.

  «published Oct. 9 in the Journal of Clinical Oncology»

  Newswise
• The trial results included a reduction in tumor activity and pain in patients with metastatic prostate cancer.

  «reducing tumor activity and pain for patients with metastatic prostate cancer»

  Newswise
• Daniel Petrylak is a professor of medicine at the Yale School of Medicine and the lead author of the study.

  «senior author of the study, published Oct. 9»

  Newswise

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms